Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3

Oncotarget

Volumn 5, Issue 12, 2014, Pages 4347-4360

  Agnoletto, Chiara ^a   Melloni, Elisabetta ^a   Casciano, Fabio ^a   Rigolin, Gian Matteo ^a   Rimondi, Erika ^b   Celeghini, Claudio ^b   Brunelli, Laura ^a   Cuneo, Antonio ^a   Secchiero, Paola ^a   Zauli, Giorgio ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

B CLL; Nutlin 3; p21; Sodium dichloroacetate

Indexed keywords

DICHLOROACETIC ACID; NUTLIN 3; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; SMALL INTERFERING RNA; IMIDAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; FEMALE; GENE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALE; MDM2 GENE; MIDDLE AGED; P21 GENE; PROTEIN EXPRESSION; PROTEIN PROCESSING; PUMA GENE; TIGAR GENE; VERY ELDERLY; GENETICS; METABOLISM;

AGED; AGED, 80 AND OVER; DICHLOROACETIC ACID; DRUG SYNERGISM; FEMALE; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PIPERAZINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905100487     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2018     Document Type: Article

References (46)

1. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008; 99: 989-94.
2. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006; 66: 8927-30.
3. Chen Y, Cairns R, Papandreou I, Koong A, Denko NC. Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS One. 2009; 4: 1-9.
4. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007; 11: 37-51.
5. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, Maguire C, Gammer TL, Mackey JR, Fulton D, Abdulkarim B, McMurtry MS, Petruk KC. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010; 2: 31ra34.
6. Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I. Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol. 2008; 109: 394-402.
7. Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C, Rosser CJ. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate. 2008; 68: 1223-31.
8. Babu E, Ramachandran S, CoothanKandaswamy V, Elangovan S, Prasad PD, Ganapathy V, Thangaraju M. Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate. Oncogene. 2011; 30: 4026-37.
9. Sun RC, Fadia M, Dahlstrom JE, Parish CR, Board PG, Blackburn AC. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat. 2010; 120: 253-60.
10. Sun RC, Board PG, Blackburn AC. Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells. Mol Cancer. 2011; 10: 142.
11. Sanchez-Arago M, Chamorro M, Cuezva JM. Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis. 2010; 31: 567-76.
12. Tong J, Xie G, He J, Li J, Pan F, Liang H. Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. J Biomed Biotechnol. 2011; 2011: 740564.
13. Ayyanathan K, Kesaraju S, Dawson-Scully K, Weissbach H. Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage. PLoS One. 2012; 7: e39949.
14. Ishiguro T, Ishiguro M, Ishiguro R, Iwai. Cotreatment with dichloroacetate and omeprazole exhibits a synergistic antiproliferative effect on malignant tumors. Oncol Lett. 2012; 3: 726-8.
15. Sanchez WY, McGee SL, Connor T, Mottram B, Wilkinson A, Whitehead JP, Vuckovic S, Catley L. Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib. Br J Cancer. 2013; 108: 1624-33.
16. Suganuma K, Miwa H, Imai N, Shikami M, Gotou M, Goto M, Mizuno S, Takahashi M, Yamamoto H, Hiramatsu A, Wakabayashi M, Watarai M, Hanamura I, Imamura A, Mihara H, Nitta M. Energy metabolism of leukemia cells: glycolysis versus oxidative phosphorylation. Leuk Lymph. 2010; 51: 2112-9.
17. Secchiero P, di Iasio MG, Gonelli A, Zauli G. The MDM2 inhibitors Nutlins as an innovative therapeutic tool for the treatment of hematological malignancies. Curr Pharm Des. 2008; 14: 2100-10.
18. Secchiero P, Zauli G. TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Op in Hematol. 2008; 15: 42-48.
19. Kumar A, Kant S, Singh SM. Novel molecular mechanisms of antitumor action of dichloroacetate against T cell lymphoma: Implication of altered glucose metabolism, pH homeostasis and cell survival regulation. Chem Biol Interact. 2012; 199: 29-37.
20. Secchiero P, Bosco R, Celeghini C, Zauli G. Recent advances in the therapeutic perspectives in nutlin-3. Curr Pharm Des. 2011; 17: 569-77.
21. Chou T, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22: 27-55.
22. Lin K, Adamson J, Johson GG, Carter A, Oates M, Wade R, Richards S, Gonzalez D, Matutes E, Dearden C, Oscier DG, Catovsky D, Pettitt AR. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration. Clin Cancer Res. 2012; 18: 4191-200.
23. Kerr DS. Review of clinical trials for mitochondrial disorders: 1997-2012. Neurotherapeutics. 2013; 10: 307-19.
24. Yeluri S, Madhok BM, Jayne DG. New horizons in cancer therapy: manipulating tumour metabolism. Biomed Res. 2010; 23: 17-23.
25. Chen LB. Mitochondrial membrane potential in living cells. Annu Rev Cell Biol. 1988; 4: 155-81.
26. Stockwin LH, Yu SX, Borgel S, Hancock C, Wolfe TL, Phillips LR, Hollingshead MG, Newton DL. Sodium Dichloroacetate (DCA) selectively targets cells with defects in the mitochondrial ETC. Int J Cancer. 2010; 127: 2510-9.
27. Leontieva OV, Blagosklonny MV. M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue. Cell Cycle. 2014; 13: 509-15.
28. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci USA. 2010; 107: 9660-4.
29. Levine AJ, Harris CR, Puzio-Cuter AM. The interfaces between signal transduction pathways: IGF-1/mTor, p53 and the Parkinson disease pathway. Oncotarget. 2012; 3: 1301-7.
30. Blagosklonny MV. The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors. Cell Cycle. 2011; 10: 2295-8.
31. van Leeuwen IM, Rao B, Sachweh MC, Lain S. An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells. Cell Cycle. 2012; 11: 1851-61.
32. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2011; 2: 222-33.
33. Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP, Lain S. Evaluation of an actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget 2010; 1: 639-50.
34. van Leeuwen IM. Cyclotherapy: opening a therapeutic window in cancer treatment. Oncotarget 2012; 3: 596-600.
35. Secchiero P, Melloni E, di Iasio MG, Tiribelli M, Rimondi E, Corallini F, Gattei V, Zauli G. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood. 2009; 113: 4300-8.
36. Melo JV, Foroni L, Brito-Babapulle V, Luzzatto L, Catovsky D. The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement. Clin Exp Immunol. 1988; 73: 23-8.
37. Re MC, Zauli G, Gibellini D, Furlini G, Ramazzotti E, Monari P, Ranieri S, Capitani S, La Placa M. Uninfected haematopoietic progenitor (CD34+) cells purified from the bone marrow of AIDS patients are committed to apoptotic cell death in culture. AIDS. 1993; 7: 1049-55.
38. Vitale M, Zamai L, Falcieri E, Zauli G, Gobbi P, Santi S, Cinti C, Weber G. IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells. Cytom Part B-Clin Cytom. 1997; 30: 61-6.
39. Zauli G, La Placa M, Vignoli M, Re MC, Gibellini D, Furlini G, Milani D, Marchisio M, Mazzoni M, Capitani S. An autocrine loop of HIV type-1 Tat protein responsible for the improved survival/proliferation capacity of permanently tat-transfected cells and required for optimal HIV-1 LTR transactivating activity. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10: 306-16.
40. Zauli G, Voltan R, Bosco R, Melloni E, Marmiroli S, Rigolin GM, Cuneo A, Secchiero P. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res. 2011; 17: 762-70.
41. Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ, Evans WE, Pieters R, Den Boer ML. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 2009; 113: 2014-21.
42. Martinez-Outschoorn UE, Lin Z, Trimmer C, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP. Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors. Cell Cycle. 2011; 10: 2504-20.
43. Gibellini D, Bassini A, Pierpaoli S, Bertolaso L, Milani D, Capitani S, La Placa M Zauli G. Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol. 1998; 160: 3891-8.
44. Secchiero P, Sun D, De Vico AL, Crowley RW, Reitz MS Jr, Zauli G, Lusso P, Gallo RC. Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans. J Virol. 1997; 71: 4571-80.
45. Zauli G, Voltan R, di Iasio MG, Bosco R, Lelloni E, Sana ME, Secchiero P. miR-34a induces the down-regulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res. 2011; 17: 2712-24.
46. Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MG, Lanza F, Secchiero P. The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status. Haematologica. 2012; 97: 1722-30.